We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+23.6%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$138M
AUM Growth
-$12.5M
Cap. Flow
-$25.1M
Cap. Flow %
-18.28%
Top 10 Hldgs %
79.11%
Holding
58
New
8
Increased
6
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.9M
2
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$1.82M
3
CFRX
ContraFect Corporation
CFRX
+$942K
4
QGEN icon
Qiagen
QGEN
+$701K
5
GOSS icon
Gossamer Bio
GOSS
+$604K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$69.5M
2
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$1.4M
3
EQM
EQM Midstream Partners, LP
EQM
+$1.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$604K
5
DERM
Dermira, Inc.
DERM
+$345K

Sector Composition

Rank Sector Weight
1 Healthcare 94.64%
2 Energy 1.7%
3 Consumer Staples 0.09%
4 Materials 0.06%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WKHS icon
51
Workhorse Group
WKHS
$30.1M
$76K 0.06%
8
– –
BCRX icon
52
BioCryst Pharmaceuticals
BCRX
$2.32B
$69K 0.05%
20,000
– –
CYTK icon
53
Cytokinetics
CYTK
$10.7B
– –
-10,000
Closed -$114K
MREO
54
Mereo BioPharma
MREO
$48.7M
– –
-77,570
Closed -$231K
XBIT icon
55
XBiotech
XBIT
$68.6M
– –
-30,000
Closed -$314K
GNMX
56
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-128,000
Closed -$19K
DOVA
57
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-50,000
Closed -$1.4M
CELG
58
DELISTED
Celgene Corp
CELG
– –
-699,648
Closed -$69.5M
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Birchview Capital held 58 positions worth $138M, down 8.3% from $150M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Birchview Capital withdrew a net $25.1M in Q4 2019, closing 6 positions and reducing 5 holdings. Its most notable exit was Celgene Corp, an estimated $69.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in Bristol-Myers Squibb Company Contingent Value Rights worth $2.11M.

  • Birchview Capital's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 699,648 shares worth $2.11M.
  • Birchview Capital added most to Bristol-Myers Squibb in Q4 2019, an estimated $41.9M increase.
  • Birchview Capital's biggest Q4 2019 reduction was EQM Midstream Partners, LP, cutting an estimated $1.39M.
  • Birchview Capital fully exited Celgene Corp in Q4 2019, selling an estimated $69.5M.
  • Birchview Capital's ten largest holdings make up 79% of its $138M portfolio in Q4 2019.
  • Birchview Capital opened 8 new positions and closed 6 in Q4 2019.
  • Birchview Capital's portfolio value fell 8.3% quarter-over-quarter to $138M.

Based on Birchview Capital's 13F filing for Q4 2019, filed 12 Feb 2020.